Afferent Pharmaceuticals
Advancing the science of chronic pain relief by targeting P2X3 receptors in nerve fibers
General Information
Get notified when Afferent Pharmaceuticals moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Afferent Pharmaceuticals
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
About Afferent Pharmaceuticals
Taxonomy: biopharmaceutical company, clinical-stage, chronic pain relief, P2X3 receptors, nerve fibers, AF-219, Phase 1 clinical studies, drug development, San Mateo, California, neuroscience, pain management, pharmaceutical research, medical innovation
Funding Rounds & Investors (4)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series C | •••••• | 6 |
|
08 Jul 2015 |
| Series B | •••••• | 3 |
|
01 Apr 2013 |
| Series A | •••••• | 1 |
|
16 Dec 2009 |
| Convertible Note | •••••• | - | 23 Oct 2009 |
Afferent Pharmaceuticals Alternatives & Competitors
Developing a transformative, non-opioid treatment for patients suffering from chronic Low Back Pain...
Your Partner for a Successful Journey to the Next Phase
Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company w...
FAQ About Afferent Pharmaceuticals
Don't just browse. Track.
Signal Tracker monitors Afferent Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
